文献速递生殖医学

选择性卵母细胞冷冻保存后尝试生育女性的生殖结局10年随访

A 10-year follow-up of reproductive outcomes in women attempting motherhood after elective oocyte cryopreservation.
PubMed 文献 · Hum Reprod · 2024-01-01

该回顾性观察性单中心研究纳入2009至2019年间在本生育诊所接受选择性卵母细胞玻璃化冷冻的843名女性,描述其至2022年5月返回诊所尝试生育时采取不同生殖治疗策略的结局。返回者231/843(27.4%),平均返回年龄40.4±3.1岁,累积活产率45.9%(106/231),全队列流产率30.7%(51/166)。选择冻卵复苏或先用新鲜自身卵母细胞进行ART取决于返回时年龄,两种策略均获得良好生殖结局。

要点

  • 843名选择性卵母细胞冷冻女性中231名(27.4%)返回尝试生育,平均返回年龄40.4±3.1岁。
  • 返回者累积活产率45.9%(106/231),全队列流产率30.7%(51/166)。
  • 仅冻卵复苏组累积活产率41.1%(37/90),仅新鲜自身卵母细胞ART组48.1%(25/52)。

核心结论

  • 选择冻卵复苏还是先用新鲜自身卵母细胞进行ART取决于返回时年龄,但两种策略均获得良好生殖结局。

研究设计与样本

  • 回顾性观察性单中心研究,纳入2009至2019年间在本生育诊所接受选择性卵母细胞玻璃化冷冻的843名女性,排除因医学或肿瘤原因行生育力保存者,描述其至2022年5月返回诊所尝试生育时采取的不同生殖治疗策略结局。

主要发现

  • 共完成1353个选择性卵母细胞冷冻周期(每名患者平均1.6±0.9个),冷冻时平均年龄36.5±2.8岁,平均抗苗勒管激素(AMH)2.3±2.0 ng/ml,174名(20.6%)有伴侣,平均冷冻13.9±9.2枚成熟卵母细胞。
  • 231名(27.4%)女性返回诊所,平均在选择性卵母细胞冷冻后39.9±23.4个月,返回时平均年龄40.4±3.1岁,平均AMH 1.5±1.5 ng/ml,158/231(68.3%)有伴侣。
  • 作为主要策略,110/231(47.6%)既往选择性卵母细胞冷冻使用者开启冻卵复苏,50/231(21.6%)行宫内人工授精,71/231(30.7%)使用新鲜自身卵母细胞行ART。
  • 全队列累积活产率为45.9%(106/231),流产率为30.7%(51/166)。
  • 共141名女性在治疗轨迹中某阶段行冻卵复苏;90/231(39.0%)仅行冻卵复苏(年龄41.6±3.0岁,每人平均复苏10.0±5.2枚卵母细胞),52/231(22.5%)仅使用新鲜自身卵母细胞行ART(平均年龄39.0±2.8岁,每人平均获取9.9±7.4枚成熟卵母细胞)。

局限性

  • 样本量和回顾性设计均为本研究的局限性。
  • 选择特定生殖治疗策略的决定基于患者在咨询治疗选项后的偏好,这妨碍了本研究对既往选择性卵母细胞冷冻使用者不同生殖治疗选项效率的直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Which reproductive treatment outcomes are observed in women who underwent elective oocyte cryopreservation (EOC) and who returned to the clinic with a desire for a child? SUMMARY ANSWER: Whether to warm oocytes or to first use fresh own oocytes for ART depends on age upon returning, but both strategies result in favorable reproductive outcomes. WHAT IS KNOWN ALREADY: Most affluent countries have observed a trend toward postponement of childbearing, and EOC is increasingly used based on the assumption that oocytes cryopreserved at a younger age may extend a woman's reproductive lifespan and mitigate her age-related fertility decline. Although most follow-up studies after EOC have focused on women who requested oocyte warming, a substantial proportion of women who do not conceive naturally will embark on fertility treatment without using their cryopreserved oocytes. Reports on reproductive outcomes in past EOC users are scarce, and the lack of reproductive treatment algorithms in this group of women hampers counseling toward the most efficient clinical strategy. STUDY DESIGN, SIZE, DURATION: This retrospective observational single-center study encompasses 843 women who had elective oocyte vitrification between 2009 and 2019 at our fertility clinic. Women who underwent fertility preservation for medical or oncological reasons were excluded. This study describes the outcomes of the diverse reproductive treatment strategies performed until May 2022 in women returning to our clinic to attempt motherhood. PARTICIPANTS/MATERIALS, SETTING, METHODS: Using descriptive statistics, patient characteristics and data of ovarian stimulation (OS) of EOC cycles were analyzed, as well as data related to OS and laboratory data of ART in women who pursued fertility treatment with and/or without using their cryopreserved oocytes. The primary outcome was live birth rate (LBR) per patient after oocyte warming and after ART using fresh oocytes. Secondary outcomes were return rate, utilization rate of the cryopreserved oocytes, laboratory outcomes upon return, and LBR per embryo transfer. A multivariable regression model was developed to identify factors associated with the decision to thaw oocytes as the primary strategy and factors associated with ongoing pregnancy upon return to the clinic. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 1353 EOC cycles (mean ± SD, 1.6 ± 0.9 per patient) were performed. At the time of EOC, the mean age was 36.5 ± 2.8 years, mean anti-Müllerian hormone (AMH) was 2.3 ± 2.0 ng/ml, and 174 (20.6%) women had a partner. On average, 13.9 ± 9.2 mature oocytes were cryopreserved. Two hundred thirty-one (27.4%) women returned to the clinic, an average of 39.9 ± 23.4 months after EOC. Upon returning, their mean age was 40.4 ± 3.1 years, mean AMH was 1.5 ± 1.5 ng/ml, and 158/231 (68.3%) patients had a partner. As a primary approach, 110/231 (47.6%) past EOC users embarked on oocyte warming, 50/231 (21.6%) had intrauterine insemination, and 71/231 (30.7%) had ART using fresh own oocytes. Cumulative LBR (CLBR) was 45.9% (106/231) notwithstanding a miscarriage rate (MR) of 30.7% (51/166) in the entire cohort. In total, 141 women performed oocyte warming at some stage in their treatment trajectory. A subset of 90/231 (39.0%) patients exclusively had oocyte warming (41.6 ± 3.0 years, with 10.0 ± 5.2 oocytes warmed per patient). 52/231 (22.5%) patients exclusively had ART using fresh own oocytes (mean age of 39.0 ± 2.8 years, with 9.9 ± 7.4 mature oocytes retrieved per patient). CLBR was 37/90 (41.1%) in the oocyte warming-only group and 25/52 (48.1%) in the OS-only group. MR/transfer was 25.0% and 29.3% in the oocyte warming-only group and the OS-only group, respectively. LIMITATIONS, REASONS FOR CAUTION: Both sample size and the retrospective design are limitations of this study. The decision to embark on a specific reproductive treatment strategy was based on patient preference, after counseling on their treatment options. This precludes direct comparison of the efficiency of reproductive treatment options in past EOC users in this study. WIDER IMPLICATIONS OF THE FINDINGS: Reporting on clinical outcomes of women who underwent EOC and returned to the clinic to embark on divergent reproductive treatment strategies is mandatory to establish guidelines for best clinical practice in this growing patient population. STUDY FUNDING/COMPETING INTEREST(S): None. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Loreti S, Darici E, Nekkebroeck J, et al. A 10-year follow-up of reproductive outcomes in women attempting motherhood after elective oocyte cryopreservation. Hum Reprod. 2024. PMID: 38145619. doi:10.1093/humrep/dead267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。